US 12,219,327 B2
Substituted isoindolines as PI3K-alpha inhibitors
Lucian V. Dipietro, Cambridge, MA (US); Kelley C. Shortsleeves, Cambridge, MA (US); Thomas H. Mclean, Cambridge, MA (US); Alexandre Larivee, Montreal (CA); Fabrizio Giordanetto, New York, NY (US); André Lescarbeau, Cambridge, MA (US); Alessandro Boezio, Cambridge, MA (US); and Hanmo Zhang, Cambridge, MA (US)
Assigned to Relay Therapeutics, Inc., Cambridge, MA (US); and D. E. Shaw Research, LLC, New York, NY (US)
Filed by Relay Therapeutics, Inc., Cambridge, MA (US); and D.E. Shaw Research, LLC, New York, NY (US)
Filed on Jun. 9, 2023, as Appl. No. 18/208,023.
Application 18/208,023 is a continuation of application No. 17/921,580, previously published as PCT/US2021/029882, filed on Apr. 29, 2021.
Claims priority of provisional application 63/066,489, filed on Aug. 17, 2020.
Claims priority of provisional application 63/017,571, filed on Apr. 29, 2020.
Prior Publication US 2023/0353959 A1, Nov. 2, 2023
Int. Cl. A61K 31/4035 (2006.01); A61B 5/00 (2006.01); C07D 209/46 (2006.01); C07D 487/04 (2006.01); H04R 25/00 (2006.01)
CPC H04R 25/554 (2013.01) [A61B 5/0026 (2013.01); A61B 5/746 (2013.01); C07D 487/04 (2013.01); H04R 2225/55 (2013.01)] 6 Claims
 
1. A compound, which is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle and the compound of claim 1, or a pharmaceutically acceptable salt thereof.